Regorafenib
CAS 755037-03-7 8 FDA-DMF suppliersSmall Molecule
Overview
Regorafenib is a multi-kinase inhibitor that targets various pathological kinases to impede cancer cell proliferation and angiogenesis. It is primarily used for the treatment of metastatic colorectal cancer and gastrointestinal stromal tumors.
Patent & exclusivity (US)
Per the FDA Orange Book (1 approved US product), the latest listed US patent on Regorafenib expires 8 Jul 2032. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
OncologyGastroenterologyHepatology
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.